Skye Bioscience (NASDAQ:SKYE) and Pacira BioSciences (NASDAQ:PCRX) Head to Head Survey

Skye Bioscience (NASDAQ:SKYE) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Earnings & Valuation

This table compares Skye Bioscience and Pacira BioSciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$37.65 million	N/A	N/A
Pacira BioSciences	$694.96 million	1.17	$41.96 million	($2.03)	-8.65

Pacira BioSciences has higher revenue and earnings than Skye Bioscience.

Analyst Ratings

This is a breakdown of current recommendations for Skye Bioscience and Pacira BioSciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	0	0	6	0	3.00
Pacira BioSciences	2	4	4	0	2.20

Skye Bioscience presently has a consensus target price of $18.67, indicating a potential upside of 353.07%. Pacira BioSciences has a consensus target price of $23.50, indicating a potential upside of 33.90%. Given Skye Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Pacira BioSciences.

Volatility & Risk

Skye Bioscience has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Institutional and Insider Ownership

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Skye Bioscience and Pacira BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-45.78%	-37.44%
Pacira BioSciences	-13.07%	13.42%	7.19%

Summary

Pacira BioSciences beats Skye Bioscience on 6 of the 11 factors compared between the two stocks.

About Skye Bioscience

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

About Pacira BioSciences

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.